Deregulation Force Strategy Rethink At Australian Firm
Australia's largest pharmaceutical cooperative, Amcal, has launched anew retail strategy to boost sales and counter possible adverse effects of proposed deregulation.
According to Asia-Pacific Trade, Amcal reported record turnover last year of almost $1 billion Australian dollars ($74.1 million), an increase of 24%, but fears it could lose up to 30% of its market share if the federal government decides to follow through plans to allow supermarkets to sell drugs when it reviews the industry in 1999.
Amcal's managing director Maurice Romano said that the company intended to extend the role of pharmacists as "specialist health providers in drug and disease management," to build a higher profile for the company's branded products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze